Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice

Related Experiment Video

Updated: Jan 3, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Van Anh Do Thi1, Hyung Min Jeon1, Sang Min Park1

  • 1Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon 34134, Korea.

Molecules and Cells
|November 26, 2019
PubMed

Insights

Engineered cancer cells secreting Interleukin (IL)-15 and its receptor IL-15Rα show enhanced anti-tumor effects. This novel cell-based vaccine strategy offers promising therapeutic potential for cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Interleukin (IL)-15 is a crucial immune modulator for cancer treatment.
  • Natural IL-15 exhibits limited efficacy due to short half-life and production challenges.
  • IL-15Rα enhances IL-15's half-life and binding affinity.

Purpose of the Study:

  • To engineer CT26 colon cancer cells for intracellular assembly and secretion of IL-15:IL-15Rα complexes.
  • To evaluate the anti-tumor efficacy of these engineered cells as a cancer vaccine and therapeutic agent.

Main Methods:

  • Double transfection of IL-15 and truncated IL-15Rα into CT26 colon cancer cells.
  • Confirmation of secreted IL-15:IL-15Rα complexes using ELISA and Co-IP.
  • Assessment of therapeutic and vaccine efficacy in mouse models using mitomycin C-inactivated cells.

Main Results:

  • Secreted IL-15:IL-15Rα complexes demonstrated superior anti-tumor activity compared to IL-15 alone.
  • Treatment with inactivated IL-15:IL-15Rα secreting cells significantly prolonged survival in tumor-bearing mice.
  • Vaccination with inactivated cells achieved 100% survival, with protection lasting over three months.
  • The anti-tumor response involved CD4+ T cells, CD8+ T cells, and NK cell cytotoxicity.

Conclusions:

  • Cell-based vaccines secreting IL-15:IL-15Rα represent a promising new strategy for cancer immunotherapy.
  • This approach overcomes the limitations of natural IL-15, offering enhanced therapeutic potential.
  • The engineered cells effectively stimulate a robust anti-tumor immune response.
Keywords:
CT26 colon carcinomaIL-15:IL15Rα complexcell-based vaccineimmunotherapyinterleukin 15 receptor alphainterleukin-15

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K